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Background: Chloroquine (CQ), alone or in combination with sulphadoxine-pyrimethamine, was widely used for
the treatment of Plasmodium falciparum and Plasmodium vivax for several decades in both Vanuatu and Solomon
Islands prior to the introduction of artemether-lumefantrine (AL) in 2008. However, the effect of chloroquine
selection on parasite population, which may affect the efficacy of lumefantrine or other partner drugs of artemisinin,
has not been well assessed. This study aims to provide baseline data on molecular markers (pfcrt and pfmdr1), along
with the origins of pfcrt, prior to the introduction of AL.
Methods: Blood spots were obtained from epidemiological surveys conducted on Tanna Island, Tafea Province,
Vanuatu and Temotu Province, Solomon Islands in 2008. Additional samples from Malaita Province, Solomon Islands
were collected as part of an artemether-lumefantrine efficacy study in 2008. Plasmodium falciparum pfcrt and pfmdr1
genes were examined for polymorphisms. Microsatellite markers flanking pfcrt were also examined to ascertain
origins of CQ resistance.
Results: Pfcrt analysis revealed 100% of parasites from Tafea Province, Vanuatu and Malaita Province, Solomon
Islands and 98% of parasites from Temotu Province, Solomon Islands carried the K76T polymorphism that confers
CQ resistance. Comparison of pfcrt allelic patterns and microsatellite markers flanking pfcrt revealed six haplotypes
with more than 70% of isolates possessing haplotypes very similar to those observed in Papua New Guinea. The
dominant (98.5%) pfmdr1 allele across all island groups was YYCND.
Conclusions: Prior to the introduction of AL in the Solomon Islands and Vanuatu, P. falciparum isolates possessed
point mutations known to confer CQ resistance and possibly associated with a decreased susceptibility to quinine
and halofantrine, but an increased susceptibility to artemisinin and lumefantrine. Overall, pfcrt allelic types and the
flanking microsatellite markers exhibited similarities to those of Papua New Guinea, suggesting these parasites share
a common ancestry. The current use of AL for both P. falciparum and P. vivax infections will enable changes in
these markers, in the absence of CQ pressure, to be monitored.
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Chloroquine-resistant (CQR) Plasmodium falciparum
parasites arose in the late 1960s and have since spread
throughout most malaria-endemic regions rendering chlo-
roquine (CQ) ineffective in many areas. The spread of CQ
resistance has been attributed to the resurgence of malaria
morbidity and mortality during the 1990s [1,2]. In 2001,
the World Health Organization (WHO) recommended
the use of artemisinin-based combination therapy (ACT)
for treatment of uncomplicated P. falciparum malaria [3].
Following this recommendation, the South Pacific coun-
tries of Vanuatu and Solomon Islands introduced ACT in
2008 [4].
CQ resistance in P. falciparum has been reported to
associate with mutations in the parasite CQ resistance
transporter gene (pfcrt) located on chromosome 7.
Molecular studies demonstrated that resistance to CQ
results from a series of mutations in pfcrt, of particular
importance is the mutation causing a change from lysine
(K) to threonine (T) at amino acid 76 [5,6]. The K76T and
11 other amino acids have been used as molecular mar-
kers for studying the evolution of CQ resistance. Various
combinations of pfcrt mutations have been identified in
different geographical locations and have been linked to
past drug exposure [7].
Worldwide, there has been at least five major independ-
ent geographical origins of CQR pfcrt alleles. Initially four
lineages were identified; one each from Indochina/Africa
(CVIET) and Melanesia (SVMNT), and two from South
America (SVMNT) [8-10]; a fifth lineage was later identi-
fied from the Philippines (C/SVMNT) [11,12]. Further-
more, SVMNT has also been linked with historical
amodiaquine use [7]. The origins of various pfcrt alleles
have been mapped using microsatellite markers flanking
pfcrt [9,10,12]. Microsatellites (MS) are short, simple,
sequence repeats, and are prolific in the P. falciparum
genome. When drug pressure exists in a parasite popula-
tion, mutations that are advantageous to the parasite, for
example those leading to drug resistance, are selected and
propagated throughout the population. The MS markers
that flank these resistance genes can also be propagated
throughout the population via a form of genetic ‘hitch-
hiking’ [9]. This leads to a reduction in the variation of
allele frequency of the MS markers closest to the locus
under selection [9].
Pfcrt mutations can also affect parasite susceptibilities to
other anti-malarial drugs. For example, wild type pfcrt
alleles confer a reduced susceptibility to lumefantrine, while
mutant alleles can result in increased sensitivity to lumefan-
trine [13]. Transfection experiments have demonstrated the
K76Tmutation as the main determinant of pfcrt-dependent
lumefantrine susceptibility [13]. Similarly, susceptibility
levels of amodiaquine have been found to vary depending
on the geographic origin of the mutant pfcrt alleles [7].The multidrug resistance gene (pfmdr1) coding for
P-glycoprotein homologue-1 (pgh-1) located on chromo-
some 5 [14-16] was also implicated in CQ resistance.
Mutations in pfmdr1 result in changes at amino acids 86,
184, 1034, 1042, and 1246, and these changes have been
associated with CQR in laboratory clones [14] although
their associations with CQR were strain specific [15].
These polymorphisms in the pfmdr1 gene were also shown
to affect parasite susceptibilities to structurally diverse anti-
malarial compounds, for example quinine, halofantrine,
mefloquine, CQ, and artemisinin in vitro [15,17]. Addition-
ally, an increase in copy number of the pfmdr1 gene was
reported to play a role in reduced parasite susceptibility to
artemisinin derivatives as well as mefloquine, halofantrine
and quinine [18-20].
Both P. falciparum and Plasmodium vivax are endemic
to the Solomon Islands and Vanuatu (except for the islands
of Aneityum and Futuna which are malaria-free). CQ was
used as first-line therapy, alone or with sulphadoxine-
pyrimethamine (SP), for both P. falciparum and P. vivax
infections until 2008. Reduced susceptibility of P. falcip-
arum parasites to CQ was first described in the Solomon
Islands in 1980, initially occurring in Western, Central,
Guadalcanal, and Malaita Provinces, extending country-
wide in later years [21,22]. In 2001, as the 28-day CQ
treatment failure rate reached 67% [22] Solomon Islands
replaced CQ with CQ plus SP as first-line therapy for
uncomplicated falciparum malaria. In Vanuatu, resistance
to CQ was first reported in 1987, following this the
Vanuatu Ministry of Health introduced a new treatment
regime in 1994, changing the treatment of uncomplicated
P. falciparum infection from CQ monotherapy to a com-
bination therapy of CQ and SP, while CQ remained the
treatment for P. vivax infections [22]. A therapeutic effi-
cacy study conducted in 2001 revealed a 16% treatment
failure rate for CQ plus SP [22]. Despite these clinical
reports, there is limited molecular data published on the
prevalence of CQR malaria in Vanuatu and the Solomon
Islands and their origins.
Vanuatu and the Solomon Islands are presently in-
tensifying malaria control countrywide and progressing
towards malaria elimination in targeted provinces. The
success of eradicating malaria is dependent on many
factors, not least of which is overcoming the challenge of
drug resistance; malaria epidemiology is an integral com-
ponent of any elimination strategy. Knowledge of baseline
drug-resistant genotypes and their changes over time in
parasite populations is critical to monitoring emergence of
drug resistance and informing treatment policy. In 2008
artemether-lumefantrine (AL) was introduced to treat
uncomplicated P. falciparum infections in both Vanuatu
and the Solomon Islands. ACT is currently the first-line
treatment for vivax malaria in both countries [4]. It is
important to document parasite molecular drug resistance
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line information for detection of future changes under AL
pressure. Furthermore, the baseline information may also
inform parasite susceptibility to companion drugs of ACT.
In this study, the occurrence and prevalence of muta-
tions in pfcrt and pfmdr1 was examined. Samples used
in this study were collected from villages across several
isolated groups of islands from Vanuatu and the Solomon
Islands in 2008. The origins of CQ resistance was also
investigated by analysing the MS loci surrounding the
pfcrt gene.Methods
Study areas and sample collection
Samples used in this paper were collected in three separ-
ate studies. Two sets were obtained from epidemiological
surveys conducted (2008) during the wet seasons in:
1. Tafea Province, Vanuatu. This was a school-based,
mass blood survey of children (2-12 years) where
73% of all children both febrile and non-febrile were
assessed for malaria infection.
2. Temotu Province, Solomon Islands. This was a
village-based mass blood survey encompassing all
ages where 50.2% of the provincial population both
febrile and non-febrile were assessed for malaria
infection.
The geographic locations and information regarding
the demographics of the populations surveyed and con-
sent process for both these surveys have been published
previously [23].
The third set of samples was from an AL (Coartem™,
Novartis) therapeutic efficacy study conducted (June to
October 2008) in the Province of Malaita, Solomon
Islands (Wini et al., unpublished). Febrile patients (2-68
years) attending Auki town clinic and Kilu’Ufi General
Hospital were recruited by the Ministry of Health staff,
Solomon Islands in collaboration with WHO. Malaita
Province lies approximately 9°S 161°E and is the second
largest and most densely populated Province of the
Solomon Islands. In these areas malaria transmission is
perennial with peaks between November and August.
Across all study sites blood samples were collected by
finger prick. A blood spot (20-30 μL) was air-dried onto
filter paper (Whatman No 3), sealed in individual plastic
bags containing desiccant and stored at room temperature
until further processing.Parasite DNA extraction and PCR speciation
Extraction of genomic DNA from blood on filter paper
and PCR to determine Plasmodium species has been
described previously [23].Parasite speciation by multiplex PCR
Plasmodium speciation was performed using species-
specific primers in a multiplex PCR as previously described
[24] to identify P. falciparum, P. vivax, Plasmodium ovale
or Plasmodium malariae infections in blood samples.
Mutations in pfcrt
The extracted DNA was used as the template for PCR
amplification of pfcrt. Initially PCR/RFLP analysis [25]
was used to determine isolates exhibiting the K76T sub-
stitution indicative of CQ resistance. Random subsets of
these samples (17 from Tafea, 50 from Temotu and 31
from Malaita Provinces) were selected for further analysis
of additional codons. DNA fragments covering 12 known
mutations in pfcrt were amplified by nested PCR as de-
scribed previously [26]. For Tafea and Temotu Provinces,
in addition to codon 76, 11 other codons were examined
(72, 74, 75, 97, 144, 160, 220, 271, 326, 356, and 371), only
four additional codons (72, 74, 75, and 97) were deter-
mined for samples from Malaita Province.
Mutations in Pfmdr1
Random subsets of samples (17 from Tafea, 37 from
Temotu and 31 from Malaita Provinces) were selected
for sequence analysis. The extracted DNA was used as
the template for PCR amplification of DNA fragments
covering five amino acid codons in pfmdr1 (86, 184,
1034, 1042, and 1246) known to affect drug resistance
levels as described previously [27].
DNA sequencing
All PCR amplifications generating a single product were
incubated with ExoSAP-ITR (USB, Cleveland, OH, USA)
to remove excess primers and nucleotides according to
the manufacturer’s protocol and then sequenced. In cases
where PCR products contained multiple bands, a single
band of expected size was excised and purified using a
NucleoSpinR extraction kit (Macherey-Nagel) and then
sequenced. Sequencing was performed using a Big Dye
Terminator kit (v.3.1) on an automated DNA sequencer,
ABI 3100 system, at the QIMR Berghofer Medical Re-
search Institute Scientific Services Analytical Facility.
Plasmodium falciparum microsatellite genotyping
For selected samples five MS markers flanking the pfcrt
gene, B5M77 (-20 kb), 2E10 (-5 kb), PE12A (+6 kb), 2H4
(+22 kb), and PE14F (+106 kb), were amplified and
analysed as described previously [9]. An additional six
P. falciparum laboratory isolates (AN001, AN018, Dd2,
C2B, PH1, and 7G8) obtained from diverse geographical
regions were analysed as reference strains [12]. MS sizes
in samples were compared to these reference strains and
calibrated accordingly.
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Prevalence of mutations in pfcrt
Sequences of pfcrt were examined and the prevalence of
mutations determined for the three island groups.
Amino acid substitutions were identified at codons 72,
76, 220, 326, and 356 whereas wild type amino acids
were observed at codons 97, 144 and 160. Initial PCR/
RFLP analysis revealed 100% of parasites from Tafea
Province, Vanuatu and Malaita Province, Solomon Islands
and 98% of parasites from Temotu Province, Solomon
Islands carried the K76T substitution indicative of CQR
(Table 1). Only one sample from the village of Neo on
Santa Cruz Island, Temotu Province exhibited the wild
type lysine (K) at codon 76 as well as cysteine (C) at codon
72, however this sample had the A220S substitution
(Table 2). All three island groups possessed pfcrt C72S
and K76T substitutions at 94 and 98% or greater, respect-
ively. Likewise, polymorphisms A220S, N326D/S and 356
L/T were 91% or greater for Tafea and Temotu Provinces
(these codons were not examined for Malaita Province).
All other codons examined indicated predominance for
wild type amino acids M74, N75, H97, A144, L160, Q271,
and R371 (Table 1).
Pfcrt allelic types
Sequence analysis of pfcrt at codons 72, 74, 75, 76, and
97 were completed for all samples investigated (17 from
Tafea, 50 from Temotu and 31 from Malaita Provinces)
and results revealed that 96/98 (98%) to be allelic type
SMNTH. One other mutant allelic type CIETH was
identified in a sample from Vanuatu while a wild type
allele CMNKH was identified in one sample from Temotu
Province, Solomon Islands.
In conjunction with these five codons, additional
PfCRT amino acids 144, 160, 220, 271, 326, 356, and 371
were examined in samples from Tafea Province, Vanuatu
and Temotu Province, Solomon Islands. Amino acids
were determined at all 12 codons investigated for 48
isolates from Tafea Province, Vanuatu and Temotu
Province, Solomon Islands, with remaining isolates having
incomplete amino acid identification at one or more
codons. Of the 51 completed sequences a predominant
allele, SMNTHALSQDLR, was identified in 38 isolatesTable 1 Prevalence (%) of amino acid substitutions in PfCRT i
Province, Vanuatu and Temotu and Malaita Provinces, Solom
Country Province n % su
72 74 75 76
Vanuatu Tafea 17 94 6 6 100
Solomon Islands Temotu 50 98 0 0 98
Malaita 31 100 0 0 100
PfCRT = Plasmodium falciparum chloroquine resistance transporter.
* = not determined.(74.5%), with the remainder being predominantly poly-
morphic at codons 271, 326 and 356. This predominant
allele was found in 83% (5/6) and 73% (33/45) of samples
from Tafea Province, Vanuatu and Temotu Province,
Solomon Islands, respectively. One sample from Port
Resolution on Tanna Island, Tafea Province possessed
allele CIETHALSE*TR (unidentified amino acids are
represented by asterisk) similar to the dominant allele
in samples originating in Thailand. In Tafea Province,
Vanuatu, 33% (3/9) of samples possessed the Q271E mu-
tation most commonly seen in Thailand. Interestingly, this
mutation was not detected in Temotu Province, Solomon
Islands despite twice the number of samples being exam-
ined. Furthermore, one CQR isolate (SMNTH**A**TR)
from the village of Ngamubulo, situated on the Reef
Islands, Temotu Province, Solomon Islands did not exhibit
the A220S polymorphism generally associated with CQR
alleles. Observed allelic types and their prevalence in the
different island groups are summarized in Table 2.
Microsatellite haplotypes
Throughout the island provinces, genotyping of five MS
markers flanking pfcrt revealed six haplotypes (based on
similarity of 4/5 markers), H1-H6. The prevalence of
each haplotype is different between the island groups
(Table 2 and Table 3).
In Temotu Province, Solomon Islands, 34 of the 50
samples were successfully typed at all five loci and re-
sulted in three haplotypes, of these 76.5% (26/34) and
20.6% (7/34) were H3 and H4, respectively, representing
97.1% of the parasite population (Table 3). These haplo-
types have been reported in PNG (AN018 and AN001
groups). Interestingly, one sample from the village of
Neo on Santa Cruz Island possessing a single A220S
polymorphism, exhibited the Southeast Asian pfcrt allelic
type and also had a MS pattern matching that of the
Thailand C2B group at all three downstream MS loci.
In Malaita Province, Solomon Islands, 28 of the 31
isolates were successfully typed at all five loci and revealed
four MS haplotypes (based on similarity of 4/5 MS
markers). Of these 71.4 (20/28) and 14.3% (4/28) were H3
and H4, respectively, representing 85.7% of parasite po-
pulation (Table 3). Three samples were classified as H1,n Plasmodium falciparum samples collected from Tafea
on Islands
bstitutions at amino acid positions in PfCRT
97 144 160 220 271 326 356 371
0 0 0 100 43 100 94 47
0 0 0 98 0 91 98 22
0 * * * * * * *
Table 2 Pfmdr1 and pfcrt genotypes and MS markers flanking pfcrt in Plasmodium falciparum samples collected from
Tafea Province, Vanuatu and Temotu and Malaita Provinces, Solomon Islands compared to reference samples
Origin (no. isolates) n H % MSa marker size (bp) AA positions
in Pfcrtb
MSc marker size (bp) AA positions
in Pfmdr1dB5M77 2E10 PE12A 2H4 PE14F
Vanuatu Tafea (n = 17) 5 1 29.4 147 174 SMNTHALSQDLR 328 184 142 YYCND
1 1 5.9 147 174 SMNTHALSQDLI 314 184 142 YYCND
1 5.9 * * SMNTHALS***R * * * YYCND
2 2 11.7 157 156 SMNTHALSE*TI * 201 148 YF*ND
5 29.4 * * SMNTHALS**TI * * * YYCND
1 5.9 * * SMNTHALS**TR * * * YYCND
1 5.9 * * SMNTHALS*STR * * * YYCND
1 5.9 * * CIETHALSE*TR * * * YYCND
Solomon Islands Temotu (n = 50) 23 3 64.7 149 174 SMNTHALSQDLR 328 192 139 YYCND
4 4 8.9 149 174 SMNTHALSQDLR 328 184 134 YYCND
1 4 2.9 149 174 SMNTHALSQDLR 328 184 136 YYCND
1 4 2.9 149 174 SMNTHALSQDLR 328 184 142 YYCND
1 2.9 * * SMNTHALSQDLR * * * YYCND
1 4 33.3 149 174 SMNTHALSQDTR 328 184 134 YYCND
1 2.9 * * SMNTHALSQDTR * * * **CND
7 5.9 * * SMNTHALSQSTI * * * **CND
2 5.9 * * SMNTHALSQ*TI * * * **CND
1 5 2.9 140 166 CMNKHALSQNIR 314 184 148 **CND
2 3 28.5 149 174 SMNTHALSQDLR 328 192 139 YYCND
1 3 14.2 149 174 SMNTHALSQDLI 328 192 139 YYCND
1 14.2 * * SMNTHALSQDLR * * * YYCND
1 16.7 * * SMNTHALSQSLR * * * **CND
1 14.2 * * SMNTHAL**STR * * * YYCND
1 14.2 * * SMNTHAL**STI * * * YYCND
1 14.2 * * SMNTH**A**TR * * * **CND
Solomon Islands Malaita (n = 31) 9 3 29 149 174 SMNTHALSQDLR 328 192 139 YYCND
11 3 35.5 149 174 SMNTHALSQDLI 260 192 139 YYCND
4 4 12.9 149 174 SMNTHALS***R 328 184 145 YYCND
1 6 3.2 149 154 SMNTHALSE*TI 328 192 142 YYCND
3 1 9.7 147 174 SMNTHALS**TI 328 184 142 YYCND
3 9.7 * * SMNTHALS**TR * * * YYCND
World reference Samples Brazil 7G8 151 190 SMNTHALSQDLR 314 194 142
Philippines PH1 149 182 CMNTHTYAQDLR 314 228 136
Thailand Dd2 149 170 CIETHALSESTI 314 204 145
Thailand C2B 149 170 CIETHALSESTI 314 184 148
Solomon Island N18 149 174 SMNTHALSQDLR 328 184 142
PNG AN001 149 174 SMNTHALSQDLR 328 184 142
PNG AN018 149 174 SMNTHALSQDLR 328 192 139
Note: Boldface amino acids represent the mutated state of that codon.
aMS microsatellite upstream of pfcrt:B5M77 (-20 kb) and 2E10 (-5 kb).
bAmino acid (AA) positions in pfcrt are 72, 74, 75, 76, 97, 144, 160, 220, 271, 326, 356, 371.
cMS microsatellite downstream of pfcrt: PE12A (+6 kb), 2H4 (+22 kb) and PE14F (+106 kb).
dAmino acid positions in pfmdr1 are 86, 184, 1034, 1042, 1246.
*not determined.
** or *** indicates 2 or 3 AA positions were not determined
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Table 3 Prevalence of MS haplotypes between different
island groups
Country Province Prevalence (%)
H1 H2 H3 H4 H5 H6
Solomon Islands Temotu 0.0 0.0 76.5 20.6 2.9 0.0
Malaita 7.1 0.0 71.4 14.3 0.0 7.1
Vanuatu Tafea 75.0 25.0 0.0 0.0 0.0 0.0
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H3 and H4. One sample was determined H6, also having
a variation at an upstream locus.
In Tanna Island, Vanuatu, eight of 17 isolates were
successfully typed at all five loci resulting in two patterns
(based on similarity of 4/5 MS markers). Of these 75%
(6/8) were determined as H1 (Table 3) showing close
identity to those observed for the Solomon N70 group
[12]. The two remaining samples, from the village of
Fetukai, had unique MS sizes at three loci, while locus
PE14F was observed to be identical to samples from the
Thailand C2B group. These two samples were classified
as H2. Interestingly, despite having the SMNTHAL in
PfCRT, they also possessed a change in amino acid from
glutamine (Q) to glutamic acid (E) at codon 271, a char-
acteristic common to both groups of samples originating
from Thailand (Dd2 and C2B).
Prevalence of mutations in pfmdr1
Sequences of pfmdr1 were analysed and the prevalence of
mutations in the three island groups determined (Table 4).
Amino acid substitutions were identified at codons 86,
184 and 1034 while only wild type codons were observed
at 1042 and 1246. Polymorphisms N86Y and S1034C were
present in 100% of samples from both countries, while
one sample from Vanuatu possessed an additional muta-
tion Y184F. The dominant pfmdr1 allele across all island
groups was YYCND. The observed allelic types in the dif-
ferent island groups are summarized in Table 2.
Discussion
CQ has been used widely in the South Pacific for many
years and has applied a strong selection pressure onTable 4 Prevalence (%) of amino acid substitutions in
PfMDR1 in Plasmodium falciparum samples collected from
Tafea Province, Vanuatu and Temotu and Malaita
Provinces, Solomon Islands
Country Province n % substitutions at amino acid
positions in PfMDR1
86 184 1034 1042 1246
Vanuatu Tafea 17 100 6 100 0 0
Solomon Islands Temotu 37 100 0 100 0 0
Malaita 31 100 0 100 0 0
PfMDR1 = Plasmodium falciparum multidrug resistance protein 1.parasite populations, which may affect the efficacy of
ACT. Vanuatu and the Solomon Islands are among the
few countries where ACT is currently used for treatment
of both P. falciparum and P. vivax malaria. Understanding
the parasite drug resistance profile at the time of ACT
introduction allows for detection of changes in future
parasite populations. It will also enable a better under-
standing of potential changes in drug resistance profiles
for both species in the absence of CQ drug pressure. In
this paper, the baseline data on pfcrt and pfmdr1 was
investigated at the time of AL introduction.
Overall results of this study indicated a dominance of
the SMNT allele across all island groups. Amino acid
analysis indicated 100% of samples examined from Tafea
Province, Vanuatu and Malaita Province, Solomon Islands,
and 98.8% of samples from Temotu Province, Solomon
Islands possessed the K76T polymorphism indicative of
CQ resistance, and possibly impaired quinine and halofan-
trine susceptibility. This also demonstrates that the CQR
pfcrt allele is at fixation in these three island group
populations of Vanuatu and Solomon Islands. The high
prevalence of CQR parasites in these two countries is not
surprising given CQ monotherapy was the primary
chemotherapeutic drug used to treat uncomplicated P.
falciparum malaria for several decades, and until rela-
tively recently, was also the treatment of choice for P.
vivax infections. Although CQ has not been used in
Vanuatu and the Solomon Islands as a monotherapy since
1994 and 1991, respectively, it was still used in combin-
ation therapy for treatment of P. vivax infections. This
continued CQ pressure provides a reasonable explanation
for the prevalence of the 76T mutation in these parasite
populations. Interestingly, published in vivo and in vitro
studies suggest the effectiveness of lumefantrine is en-
hanced in P. falciparum parasites carrying the pfcrt K76T
mutation [13]. This suggests that lumefantrine is an ideal
ACT partner drug to use in Vanuatu and the Solomon
Islands as both these regions exhibit high levels of CQ
resistance.
All samples exhibiting the K76T polymorphism also
possessed additional mutations occurring in at least one
of the following codons 220, 326, 356, and 371. While
SMNTHALSQDLR was predominant on all three island
groups, variation in pfcrt genotypes exists not only be-
tween these two countries but also within island groups.
In Temotu Province, one of 50 samples analysed retained
a wild type K76 in conjunction with a single A220S poly-
morphism (genotype CMNKHALSQNIR). Although the
A220S polymorphism in pfcrt has been shown to increase
the level of CQ resistance when co-existing with K76T, it
is unlikely that a single A220S polymorphism is sufficient
to confer CQR [28]. In contrast, another isolate from the
village of Ngamubulo situated on the Reef Islands did not
exhibit the A220S substitution generally associated with
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occurrence of the A220 in combination with the K76T
mutation, although not common, has been previously
documented in isolates from the Philippines, as well as
India and China [12,29,30]. Q is found at codon 271 in all
samples, including reference samples, except those origin-
ating in Thailand, which predominantly contain an E at
this position. Interestingly, 43% of samples from Tafea
Province, Vanuatu contained the Q271E substitution. At
this point the drug pressure that selects for this poly-
morphism is not understood; however, it may be indicative
of changes in drug sensitivity profiles and/or the sub-
sequent sweep of drug resistant alleles throughout the
region, hence this codon may be a key amino acid for
future surveillance studies.
Overall, results indicated that 74.5% (38/51) of samples
collected from Tafea Province, Vanuatu and Temotu
Province, Solomon Islands, for which all 12 pfcrt codons
could be determined, had a pfcrt allelic type identical to
those from Papua New Guinea (PNG). This may indicate
a gene flow of parasite alleles between these island groups
and suggests that malaria drug resistance in these prov-
inces is similar to PNG. At this time it is unclear if clinical
drug resistance differences exist between Tafea Province,
Vanuatu and Temotu Province, Solomon Islands, however
pfcrt analysis of P. falciparum samples collected from these
locations predict similar drug susceptibilities. Furthermore,
the SMNTH allelic type of pfcrt in these island groups
suggests a past parasite exposure to amodiaquine (AQ) [7]
although no evidence of AQ use in either Vanuatu or the
Solomon Islands is evident. AQ was however introduced
in PNG in 1966 and given its close geographical proxim-
ity, the likelihood of drug resistance genotypes becoming
established in the neighbouring countries of Solomon
Islands and Vanuatu seems predictable.
Analysis of five MS markers flanking pfcrt was under-
taken to determine whether parasites harbouring muta-
tions that conferred CQR evolved locally or originated via
gene flow from other countries. Overall, 70 of 98 samples
from three island groups were typed revealing six MS
haplotypes. There were difficulties in obtaining MS data
for many of the samples analysed, particularly from Tanna
Island and Temotu Province; this was possibly due to low
levels of parasitaemia in these samples as these were
obtained from cross-sectional surveys of villagers most of
whom were asymptomatic and had low parasitaemia at
time of survey. Interestingly, also in Tafea and Temotu
Provinces there was a high incidence of asymptomatic
infections. In Tafea Province only 28% of children that
were slide positive for malaria were febrile while in
Temotu Province only 14% of all ages tested that were
slide positive for malaria were febrile [31]. This suggests in
these regions that a high proportion of people infected
with malaria were asymptomatic. In comparison 63% ofsamples collected from Malaita Province were from febrile
patients attending the clinic or hospital. This implies that
only sampling from symptomatic individuals (ie. those
attending clinics or hospitals) has the potential to miss
many positive malaria cases and this may lead to un-
detected genotypes circulating within populations.
Interestingly, the distribution and prevalence of the six
haplotypes were different between the island groups. H3
and H4 were predominant haplotypes in both Temotu
and Malaita Provinces, Solomon Islands. Both these
haplotypes were also dominant types in PNG [10,12].
The MS and the pfcrt typing results strongly indicate
that CQR parasites in two different provinces of Solomon
Islands share the same origin as those from PNG and may
have resulted from a spread via PNG. Minor haplotypes
were also observed in these two island groups, H5 was
present in Temotu while H1 and H6 were in Malaita
Province. H5 has a distinct MS pattern upstream to
pfcrt and has a wild type pfcrt representing a minor CQ-
sensitive parasite population. The minor types H1 and H6,
have small variations to H3 and H4, and may have resul-
ted from genetic drift.
In Tafea Province, Vanuatu, H1 appears to be the dom-
inant haplotype albeit the sample number is relatively
small. Although there is variation, it is closely related to
H4, which has been reported in samples from Guadalcanal,
Solomon Islands previously [12]. Therefore, parasites in
this province may have spread from Solomon Islands or
PNG. The haplotype H2 (n = 2) observed in this location
may have been generated from a recombination be-
tween Southeast Asian and PNG parasites. The Q271E
polymorphism detected in these two parasites, which is
common to Southeast Asian CQR parasites, and the
presence of Southeast Asian CQR pfcrt allele in the
province support this hypothesis.
Interactions between pfcrt and pfmdr1 mutations and
their combined effect on drug resistance are not clear.
Like pfcrt, direct evidence has demonstrated that point
mutations in pfmdr1 can confer resistance to CQ, meflo-
quine, quinine, and halofantrine [15]. It has been sug-
gested that the response of CQR falciparum parasites to
CQ is associated not only with the pfcrt genotype but
also the pfmdr1 mutations with which they are coupled
[7]. In this study the dominant (98.5%) pfmdr1 allele across
all island groups was YYCND, only one isolate from
Vanuatu possessed a YF*ND allele. Studies have sug-
gested that the Y184F mutation is associated with low-
level resistance to AL [32] but as yet there has been no
consensus for the role it plays in CQ resistance. The
change in amino acid from asparagine to tyrosine N86Y
has been associated with CQ resistance in some investiga-
tions [33-36] but not others [37-40]; this polymorphism
has also been implicated in playing a modulating role in
reducing the susceptibility of parasites to amodiaquine
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CQ. A clinical trial in Zanzibar, in which pfcrt K76T and
pfmdr1 N86Y frequencies were determined before AL
administration and then again in all recurrent parasites
during a follow-up period of 42 days, showed a significant
increase in the occurrence of pfmdr1 N86, suggesting N86
as a potential marker of lumefantrine resistance in vivo
[45]. Thus, future surveillance studies in Vanuatu and the
Solomon Islands, post implementation of AL, will be of
interest to see if there are similar changes in the frequency
of pfmdr1 mutations.
Conclusions
This study provides a clear indication of widespread CQ
resistance in both the Solomon Islands and Vanuatu
at the time of AL introduction. Overall the pfcrt genotypes
and the MS markers flanking them in samples from Tafea
Province, Vanuatu, and Temotu and Malaita Provinces,
Solomon Islands exhibited similarities to those of PNG
suggesting that malaria drug resistance profiles are also
similar between these countries. The recent introduction
and use of AL throughout this region as first-line treat-
ment for both P. falciparum and P. vivax infections, war-
rants continued surveillance not only to monitor baseline
but also to observe correlative changes in the pfcrt allele
in the absence of CQ pressure.
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